GELS
Gelteq Ltd
NASDAQ · Pharmaceuticals
$0.81
+0.01 (+0.76%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.14M | 1.91M | 1.66M |
| Net Income | 363.4K | 328.9K | 295.4K |
| EPS | — | — | — |
| Profit Margin | 17.0% | 17.2% | 17.7% |
| Rev Growth | +7.4% | -9.8% | +4.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.15M | 1.31M | 1.18M |
| Total Equity | 6.07M | 6.78M | 6.33M |
| D/E Ratio | 0.19 | 0.19 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 556.5K | 495.2K | 517.1K |
| Free Cash Flow | 529.0K | 411.8K | 446.0K |